Our platform technology allows us to engineer novel Hybrid Interferons targeted against specific diseases, each with a large unmet medical need and clear commercial market.

Our lead candidate - Alfacyte - is a broad-spectrum antiviral in development as a therapeutic for RSV.

Latest News

Drug Discovery World article: Hybrid interferons: Preparing for the next pandemic

'ILC Therapeutics' CEO Owain Millington has authored an article in the winter issue of Drug Discovery World, on some of the areas of unmet need in infectious disease, and where the search for pleiotropic, broad-spectrum antivirals could lead drug development.

Read More on Drug Discovery World article: Hybrid interferons: Preparing for the next pandemic »

Manufacturing Chemist article: Hybrid interferons: developing a novel drug class

Dawn Firmin, ILC Therapeutics Chief Operating Officer, spoke with Manufacturing Chemist about how the Company is pioneering a novel drug class called hybrid interferons.
Read More on Manufacturing Chemist article: Hybrid interferons: developing a novel drug class »

ILC Therapeutics completes £2.5m financing and bolsters C-suite

ILC Therapeutics, a specialist developer of hybrid interferons, a new drug class engineered for improved therapeutic profiles across multiple indications, announces that it has successfully completed a fundraise of £2.5m.

Read More on ILC Therapeutics completes £2.5m financing and bolsters C-suite »